Notification according to label change order _ [Kyprolis Inj. 30mg(Carfilzomib) and one other case]

In accordance with the results of the drug re-examination, the Ministry of Food and Drug Safety’s Label Change Order (Drug Safety Evaluation Division-273, 2024.02.01) has changed the precautions for the use of the following products.

As a result, we would like to inform you that the product information for this product has been changed as of May 01, 2024.

• Product: Kyprolis Inj. 30mg (Carfilzomib), Kyprolis Inj. 60mg (Carfilzomib)
• Changes: Precautions for Use [2. Adverse Reactions 3) Results of Post-Market Research in Korea
• Label change date: May 01, 2024 (3 months after MFDS’s instruction date)
• Attachments: Ministry of Food and Drug Safety Label Change Order official letter, Changes, And comparative table [Please refer to our Korean website (www.amgen.co.kr)]  

For more information, please refer to the revised product information (date of revision: May 1, 2024) attached to the product, and you can also check the product information on our website (www.amgen.co.kr).